English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The six-carbon circular non-proteinogenic compound  l -pipecolic acid is an important chiral drug intermediate with many applications in the pharmaceutical industry. In the present study, we developed a metabolically engineered strain of  Escherichia coli  for the overproduction of  l -pipecolic acid from glucose.    Results  The metabolic pathway from  l -lysine to  l -pipecolic acid was constructed initially by introducing lysine cyclodeaminase (LCD). Next,  l -lysine metabolic flux from glucose was amplified by the plasmid-based overexpression of  dapA, lysC,  and  lysA  under the control of the strong  trc  promoter to increase the biosynthetic pool of the precursor  l -lysine. Additionally, since the catalytic efficiency of the key enzyme LCD is limited by the cofactor NAD + , the intracellular pyridine nucleotide concentration was rebalanced by expressing the  pntAB  gene encoding the transhydrogenase, which elevated the proportion of LCD with bound NAD +  and enhanced  l -pipecolic acid production significantly. Further, optimization of Fe 2+  and surfactant in the fermentation process resulted in 5.33 g/L  l -pipecolic acid, with a yield of 0.13 g/g of glucose via fed-batch cultivation.    Conclusions  We expanded the metabolic pathway for the synthesis of the chiral pharmaceutical intermediate  l -pipecolic acid in  E. coli.  Using the engineered  E. coli,  a fast and efficient fermentative production of  l -pipecolic acid was achieved. This strategy could be applied to the biosynthesis of other commercially and industrially important chiral compounds containing piperidine rings.    Electronic supplementary material  The online version of this article (doi:10.1186/s12934-017-0666-0) contains supplementary material, which is available to authorized users.

Expanding metabolic pathway for de novo biosynthesis of the chiral pharmaceutical intermediate l-pipecolic acid in Escherichia coli